The standardized, objective Q-Motor data supported the interpretation that a strong placebo effect had driven the large TMS benefits observed in the placebo group in PRIDE-HD. It was very helpful to have these observation at hand, particularly in light of the changes seen in the Unified Huntington’s Disease Rating Scale – Total Motor Score (UHDRS-TMS). Jointly, the data supported a central effect of pridopidine and provided the rational for embarking into the PROOF-HD phase III study. This observation corroborated the Total Functional Capacity (TFC) effect observed at 45mg BID. In contrast, the placebo group showed deterioration, i.e. In PRIDE-HD, several Q-Motor measures provided evidence for a motor benefit of patients treated with pridopidine – particularly in the 45 mg BID arm – see figure below (modified from Reilmann et al., 2019). Q-Motor (Quantitative-Motor) assessments have been applied in multiple clinical trials and biomarker studies in HD. Ralf Reilmann, MD, PhD is the Global Coordinating Principal Investigator – Europe, for PROOF-HD. Objective evidence for effect of pridopidine
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |